AADi in-licenses Celgene's ABI-009

20 May 2014

US clinical-stage biopharma company AADi says it has in-licensed ABI-009 from biotech firm Celgene (Nasdaq: CELG). Financial terms of the agreement were not revealed.

ABI-009 is the nanoparticle albumin-bound (nab version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the nab platform that is behind the success of Celgene’s Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound).

As part of the licensing accord, AADi plans to develop ABI-009 initially in oncology and cardiovascular indications. A Phase I trial for ABI-009 has been completed in patients with advanced non-hematologic malignancies in which the drug was well tolerated with evidence of activity in heavily pretreated patients. Celgene has the option to reacquire ABI-009 at various stages in development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK